MASSDEVICE ON CALL — Medistem Inc. (PINK:MEDS) partnered with Yale University on diabetes treatment using stem cells to generate pancreatic islets from endometrial regenerative cells.

Pancreatic islets effectively treated diabetes in animal models, and Medistem is also studying ERCs as therapy for critical limb ischemia and congestive heart failure, both complications of uncontrolled diabetes.